Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline [Yahoo! Finance]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Yahoo! Finance
Neutral to Buy and boosted its price target from $115 to $142, highlighting the company's key position in oncology. According to the firm, BioNTech SE (NASDAQ:BNTX) stands “at the nexus of significant developments occurring in the oncology field,” particularly in next-generation immuno-oncology and antibody-drug conjugates (ADCs). Goldman Sachs noted BioNTech's extensive portfolio of programs aimed at an estimated market worth more than $100 billion, with key results coming in 2026 that could position the company as a pioneer in the next stage of oncology treatments. However, Goldman Sachs recognized potential rivalry in BioNTech's clinical development domains, including competition from other bispecific antibody companies and late-stage ADC initiatives. However, it determined that BioNTech has a “unique risk/reward opportunity” in the rapidly changing oncology field. BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that develops and commercializes novel immunotherapi
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech (NASDAQ:BNTX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $113.00 price target on the stock.MarketBeat
- BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People OfficerGlobeNewswire
- BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.MarketBeat
- BioNTech (NASDAQ:BNTX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.MarketBeat
- BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan [Yahoo! Finance]Yahoo! Finance
BNTX
Earnings
- 11/3/25 - Miss
BNTX
Sec Filings
- 1/28/26 - Form 6-K
- 1/14/26 - Form 6-K
- 1/12/26 - Form 6-K
- BNTX's page on the SEC website